Haoran Jiang
Haoran Jiang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Alem W. Kahsai
Department of Medicine, Duke University Medical Center
1 shared publication - Alex Shaginian
HitGen Inc., Chengdu, China
1 shared publication Alexandria L. Soto
1 shared publication- Alyssa Grogan
Department of Medicine and
1 shared publication - Andrew P. Landstrom
Department of Pediatrics, Division of Cardiology, Children’s Hospital of Philadelphia, Philadelphia & Perelman School of Medicine, University of Pennsylvania, Philadelphia (B.B., A.P.L.).
1 shared publication - Arun Jyothidasan
Department of Medicine and
1 shared publication
Latest Publications
- Open Access
- 6 December 2025
- Published by Elsevier in JTCVS Open
- Vol. 29
An early nationwide analysis on the continuous distribution of lung-involved multiorgan transplantation
- 6 December 2025
- Published by Elsevier in JTCVS Open
- Vol. 29
Open AccessAn early nationwide analysis on the continuous distribution of lung-involved multiorgan transplantation
- Open Access
- 16 October 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (24)
A positive allosteric modulator of the β1AR with antagonist activity for catecholaminergic polymorphic ventricular tachycardia
Orthosteric beta blockers represent the leading pharmacological intervention for managing heart diseases owing to their ability to competitively antagonize β-adrenergic receptors (βARs). However, their use is often limited by adverse effects such as fatigue, hypotension, and reduced exercise capacity, due in part to nonselective inhibition of multiple βAR subtypes. These challenges are particularly problematic in treating catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease characterized by lethal tachyarrhythmias directly triggered by cardiac β 1 AR activation. To identify small-molecule allosteric modulators of the β 1 AR with enhanced subtype specificity and robust functional antagonism of β 1 AR-mediated signaling, we conducted a DNA-encoded small-molecule library screen and discovered Compound 11 (C11). C11 selectively potentiates the binding affinity of orthosteric agonists to the β 1 AR while potently inhibiting downstream signaling after β 1 AR activation. C11 prevents agonist-induced spontaneous contractile activity, Ca 2+ release events, and exercise-induced ventricular tachycardia in the CSQ2 –/– murine model of CPVT. Our studies demonstrate that C11 belongs to an emerging class of allosteric modulators termed positive allosteric modulator antagonists that positively modulate agonist binding but block downstream function. Its pharmacological properties and selective functional antagonism of β 1 AR-mediated signaling make C11 a promising therapeutic candidate for the treatment of CPVT and other forms of cardiac disease associated with excessive β 1 AR activation.
- 16 October 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (24)
Open AccessA positive allosteric modulator of the β1AR with antagonist activity for catecholaminergic polymorphic ventricular tachycardia
Orthosteric beta blockers represent the leading pharmacological intervention for managing heart diseases owing to their ability to competitively antagonize β-adrenergic receptors (βARs). However, their use is often limited by adverse effects such as fatigue, hypotension, and reduced exercise capacity, due in part to nonselective inhibition of multiple βAR subtypes. These challenges are particularly problematic in treating catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease characterized by lethal tachyarrhythmias directly triggered by cardiac β 1 AR activation. To identify small-molecule allosteric modulators of the β 1 AR with enhanced subtype specificity and robust functional antagonism of β 1 AR-mediated signaling, we conducted a DNA-encoded small-molecule library screen and discovered Compound 11 (C11). C11 selectively potentiates the binding affinity of orthosteric agonists to the β 1 AR while potently inhibiting downstream signaling after β 1 AR activation. C11 prevents agonist-induced spontaneous contractile activity, Ca 2+ release events, and exercise-induced ventricular tachycardia in the CSQ2 –/– murine model of CPVT. Our studies demonstrate that C11 belongs to an emerging class of allosteric modulators termed positive allosteric modulator antagonists that positively modulate agonist binding but block downstream function. Its pharmacological properties and selective functional antagonism of β 1 AR-mediated signaling make C11 a promising therapeutic candidate for the treatment of CPVT and other forms of cardiac disease associated with excessive β 1 AR activation.